{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:25:30Z","timestamp":1760243130977,"version":"build-2065373602"},"reference-count":37,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2015,7,17]],"date-time":"2015-07-17T00:00:00Z","timestamp":1437091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Coxsackievirus A16 (CA16) and enterovirus 71 (EV71), both of which can cause hand, foot and mouth disease (HFMD), are responsible for large epidemics in Asian and Pacific areas. Although inactivated EV71 vaccines have completed testing in phase III clinical trials in Mainland China, CA16 vaccines are still under development. A Vero cell-based inactivated CA16 vaccine was developed by our group. Screening identified a CA16 vaccine strain (CC024) isolated from HFMD patients, which had broad cross-protective abilities and satisfied all requirements for vaccine production. Identification of the biological characteristics showed that the CA16CC024 strain had the highest titer (107.5 CCID50\/mL) in Vero cells, which would benefit the development of an EV71\/CA16 divalent vaccine. A potential vaccine manufacturing process was established, including the selection of optimal time for virus harvesting, membrane for diafiltration and concentration, gel-filtration chromatography for the down-stream virus purification and virus inactivation method. Altogether, the analyses suggested that the CC-16, a limiting dilution clone of the CC024 strain, with good genetic stability, high titer and broad-spectrum immunogenicity, would be the best candidate strain for a CA16 inactivated vaccine. Therefore, our study provides valuable information for the development of a Vero cell-based CA16 or EV71-CA16 divalent inactivated vaccine.<\/jats:p>","DOI":"10.3390\/v7072803","type":"journal-article","created":{"date-parts":[[2015,7,17]],"date-time":"2015-07-17T11:18:48Z","timestamp":1437131928000},"page":"3891-3909","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Optimization and Characterization of Candidate Strain for Coxsackievirus A16 Inactivated Vaccine"],"prefix":"10.3390","volume":"7","author":[{"given":"Jingliang","family":"Li","sequence":"first","affiliation":[{"name":"First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanchen","family":"Liu","sequence":"additional","affiliation":[{"name":"First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[{"name":"First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxin","family":"Yang","sequence":"additional","affiliation":[{"name":"First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junliang","family":"Chang","sequence":"additional","affiliation":[{"name":"First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Fang","family":"Yu","sequence":"additional","affiliation":[{"name":"First Hospital of Jilin University, Institute of Virology and AIDS Research, 130061 Changchun, China"},{"name":"Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD 21205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2015,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1574-6976.2002.tb00601.x","article-title":"An overview of the evolution of enterovirus 71 and its clinical and public health significance","volume":"26","author":"McMinn","year":"2002","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e37206","DOI":"10.1371\/journal.pone.0037206","article-title":"Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants","volume":"7","author":"Zhu","year":"2012","journal-title":"PLoS ONE"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0140-6736(12)61764-4","article-title":"Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: A randomised, double-blind, placebo-controlled phase 2 clinical trial","volume":"381","author":"Zhu","year":"2013","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jcv.2009.02.002","article-title":"An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China","volume":"44","author":"Zhang","year":"2009","journal-title":"J. Clin. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/BF02879323","article-title":"The complete genome of Enterovirus 71 China strain","volume":"44","author":"Yang","year":"2001","journal-title":"Sci. China Ser. C Life Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.4269\/ajtmh.2007.77.188","article-title":"An eight-year study of epidemiologic features of enterovirus 71 infection in Taiwan","volume":"77","author":"Chen","year":"2007","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3201\/eid1510.090594","article-title":"Rhombencephalitis and coxsackievirus A16","volume":"15","author":"Goto","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.47102\/annals-acadmedsg.V38N2p106","article-title":"Epidemiology and control of hand, foot and mouth disease in Singapore, 2001\u20132007","volume":"38","author":"Ang","year":"2009","journal-title":"Ann. Acad. Med. Singapore"},{"key":"ref_9","first-page":"615","article-title":"Report of an outbreak of febrile illness with pharyngeal lesions and exanthem: Toronto, summer 1957; isolation of group A Coxsackie virus","volume":"79","author":"Robinson","year":"1958","journal-title":"Can. Med. Assoc. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1017\/S002217240006472X","article-title":"A survey of coxsackie A16 virus antibodies in human sera","volume":"93","author":"Urquhart","year":"1984","journal-title":"J. Hyg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/01.inf.0000115950.63906.78","article-title":"Fatal coxsackievirus A16 infection","volume":"23","author":"Wang","year":"2004","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM196305092681904","article-title":"Fatal infection in an infant associated with Coxsackie virus group A, type 16","volume":"268","author":"Wright","year":"1963","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00705-010-0722-0","article-title":"Emergence of enterovirus 71 \u201cdouble-recombinant\u201d strains belonging to a novel genotype D originating from southern China: First evidence for combination of intratypic and intertypic recombination events in EV71","volume":"155","author":"Yip","year":"2010","journal-title":"Arch. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.virol.2012.06.026","article-title":"The effect of enterovirus 71 immunization on neuropathogenesis and protein expression profiles in the thalamus of infected rhesus neonates","volume":"432","author":"Chen","year":"2012","journal-title":"Virology"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhu, Z., Yang, W., Ren, J., Tan, X., Wang, Y., Mao, N., Xu, S., Zhu, S., and Cui, A. (2010). An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol. J., 7.","DOI":"10.1186\/1743-422X-7-94"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11684-012-0237-z","article-title":"Progress on the research and development of human enterovirus 71 (EV71) vaccines","volume":"7","author":"Liang","year":"2013","journal-title":"Front. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1472-765X.2010.02805.x","article-title":"In vitro anti-enterovirus 71 activity of gallic acid from Woodfordia fruticosa flowers","volume":"50","author":"Choi","year":"2010","journal-title":"Lett. Appl. Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Liang, Z., and Wang, J. (2014). EV71 vaccine, an invaluable gift for children. Clin. Transl. Immunol., 3.","DOI":"10.1038\/cti.2014.24"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1016\/j.vaccine.2012.08.071","article-title":"A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge","volume":"30","author":"Liu","year":"2012","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00705-011-1136-3","article-title":"Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71","volume":"157","author":"Mao","year":"2012","journal-title":"Arch. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.4161\/hv.21739","article-title":"Production of EV71 vaccine candidates","volume":"8","author":"Chong","year":"2012","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1099\/vir.0.063560-0","article-title":"Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates","volume":"95","author":"Li","year":"2014","journal-title":"J. Gen. Virol."},{"key":"ref_23","first-page":"493","article-title":"A simple method of estimating fifity percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Hyg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e94746","DOI":"10.1371\/journal.pone.0094746","article-title":"Circulating HFMD-associated coxsackievirus A16 is genetically and phenotypically distinct from the prototype CV-A16","volume":"9","author":"Wei","year":"2014","journal-title":"PLoS ONE"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1128\/jvi.71.12.9743-9752.1997","article-title":"Dissecting the roles of VP0 cleavage and RNA packaging in picornavirus capsid stabilization: The structure of empty capsids of foot-and-mouth disease virus","volume":"71","author":"Curry","year":"1997","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e49973","DOI":"10.1371\/journal.pone.0049973","article-title":"Immunological and biochemical characterization of coxsackie virus A16 viral particles","volume":"7","author":"Chong","year":"2012","journal-title":"PLoS ONE"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/pro.5560051107","article-title":"Cleavage site analysis in picornaviral polyproteins: Discovering cellular targets by neural networks","volume":"5","author":"Blom","year":"1996","journal-title":"Protein Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0264-410X(01)00385-1","article-title":"Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus","volume":"20","author":"Wu","year":"2001","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1016\/j.vaccine.2011.04.010","article-title":"Identification and characterization of a cross-neutralization epitope of Enterovirus 71","volume":"29","author":"Liu","year":"2011","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.vaccine.2011.11.087","article-title":"Selection and characterization of vaccine strain for Enterovirus 71 vaccine development","volume":"30","author":"Chang","year":"2012","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000148922","article-title":"Epidemic of hand, foot and mouth disease associated with enterovirus 71 infection","volume":"9","author":"Hagiwara","year":"1978","journal-title":"Intervirology"},{"key":"ref_32","first-page":"45","article-title":"Evolution of vaccine poliovirus strains","volume":"53","author":"Iakovenko","year":"2008","journal-title":"Vopr. Virusol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.micinf.2007.06.002","article-title":"Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide","volume":"9","author":"Foo","year":"2007","journal-title":"Microbes. Infect."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jviromet.2013.04.020","article-title":"Comparison of initial feasibility of host cell lines for viral vaccine production","volume":"193","author":"Vlecken","year":"2013","journal-title":"J. Virol. Methods"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/bit.21109","article-title":"Purification of cell culture-derived human influenza A virus by size-exclusion and anion-exchange chromatography","volume":"96","author":"Kalbfuss","year":"2007","journal-title":"Biotechnol. Bioeng."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1128\/jvi.70.8.5519-5524.1996","article-title":"African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses","volume":"70","author":"Govorkova","year":"1996","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1016\/j.vaccine.2011.01.094","article-title":"Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine","volume":"29","author":"Chen","year":"2011","journal-title":"Vaccine"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/7\/7\/2803\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:49:19Z","timestamp":1760215759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/7\/7\/2803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,17]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,7]]}},"alternative-id":["v7072803"],"URL":"https:\/\/doi.org\/10.3390\/v7072803","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2015,7,17]]}}}